Drug Trial Radar · NCT05083364
Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease
Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
62
Actual
Start
Feb 1, 2022
Primary completion
Sep 10, 2025
Study completion Sep 10, 2025
Sponsor
- Lead sponsor
- Arrowhead PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Oct 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of AROC3-1001 is to evaluate the safety, tolerability, pharmacokinetics and/or pharmacodynamics in adult healthy volunteers (HVs) and in adult patients with complement-mediated renal disease (C3 Glomerulopathy \[C3G\] and IgA Nephropathy \[IgAN\]). In Part 1 of the study, HVs will receive either one or two doses of ARO-C3 or placebo. In Part 2 of the study, adult patients with C3G/IgAN will receive 3 open-label doses of ARO-C3. Dose levels in Part 2 will be determined based on cumulative safety and pharmacodynamic data from Part 1.
Conditions
- C3 Glomerulopathy
- IgA Nephropathy
Interventions
ARO-C3Drug
ARO-C3 for sc injection
PlaceboDrug
sterile normal saline (0.9% NaCl) for sc injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AEs) and/or Serious Adverse Events (SAEs) at Day 169Time frame: up to day 169 (End of Study [EOS])
Locations
16 sites in 7 countries. Site status is shown where the registry gives one.
Research Site 1
Camperdown, New South Wales, Australia
Research Site 3
Concord, New South Wales, Australia
Research Site 2
Clayton, Victoria, Australia
Research Site 2
Tbilisi, Georgia
Research Site 2
Cologne, Germany
Research Site 4
Erlangen, Germany
Research Site
Auckland, New Zealand
Research Site 3
Daegu, South Korea
Research Site 6
Soeul, South Korea
Research Site 8
Soeul, South Korea
Research Site 1
Gamcheon, Busan, South Korea
Research Site 2
Haeundae, Busan, South Korea
Research Site 4
Goyang-si, Gyeonggi-do, South Korea
Research Site 2
Bangkok, Thailand
Research Site 3
Chiang Mai, Thailand
Research Site 4
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.